• UCB reached an agreement with the U.S. government that exempts it from Section 232 pharmaceutical tariffs on current products.
• The deal also shields future launches from U.S. pricing mandates, supporting continued investment in U.S. R&D and manufacturing.
• UCB committed to a more balanced pricing approach for future launches across developed markets, including participation in the GENEROUS program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief via PR Newswire (Ref. ID: CL37436) on August 31, 2026, and is solely responsible for the information contained therein.